4/14
04:59 am
tak
AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]
Low
Report
AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]
4/8
10:00 am
tak
Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".
Low
Report
Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".
4/3
02:10 pm
tak
Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]
Medium
Report
Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]
4/3
01:47 pm
tak
Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]
Medium
Report
Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]
4/1
01:47 pm
tak
DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]
Low
Report
DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]
3/30
01:06 pm
tak
Massachusetts' largest biopharma employer to lay off 237 in Cambridge [Yahoo! Finance]
Low
Report
Massachusetts' largest biopharma employer to lay off 237 in Cambridge [Yahoo! Finance]
3/30
02:16 am
tak
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner [Yahoo! Finance]
Low
Report
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner [Yahoo! Finance]
3/28
10:13 pm
tak
Takeda Pharmaceutical Showcases Strong Phase III Psoriasis Data for Zasocitinib, Eyes 2027 Launch [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical Showcases Strong Phase III Psoriasis Data for Zasocitinib, Eyes 2027 Launch [Yahoo! Finance]
3/28
03:00 pm
tak
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Low
Report
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
3/11
09:31 pm
tak
????????????:2026???2036?????????? [CNET News]
Low
Report
????????????:2026???2036?????????? [CNET News]
3/8
12:08 pm
tak
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment [Yahoo! Finance]
Low
Report
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment [Yahoo! Finance]
3/5
07:56 am
tak
Takeda Pharmaceutical (TAK) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Takeda Pharmaceutical (TAK) was upgraded by Zacks Research from "strong sell" to "hold".
3/4
04:31 pm
tak
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/4
12:51 pm
tak
Takeda plans to lay off 400 employees in US - report [Seeking Alpha]
Low
Report
Takeda plans to lay off 400 employees in US - report [Seeking Alpha]
3/2
02:00 am
tak
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Low
Report
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
2/19
12:00 pm
tak
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Low
Report
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
2/16
02:23 am
tak
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months [Yahoo! Finance]
Low
Report
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months [Yahoo! Finance]
2/10
03:15 am
tak
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Low
Report
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
2/2
03:24 am
tak
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
Low
Report
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
2/2
12:26 am
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
1/31
09:57 am
tak
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
Low
Report
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
1/31
01:33 am
tak
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
Low
Report
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
1/30
02:16 pm
tak
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
Low
Report
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
1/29
01:37 am
tak
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Medium
Report
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
1/22
07:45 am
tak
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
Low
Report
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹